Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937094 | 1.00 | KIF11 (0.45) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL8996214 | 1.00 | KIF11 (0.45) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL1734544 | 0.87 | CA12 (0.46) | CA12CA1MMP2MEN1KMT2A | |
| SCHEMBL1734546 | 0.87 | CA12 (0.46) | CA12CA1MMP2MEN1KMT2A | |
| SCHEMBL14509044 | 0.87 | CA12 (0.46) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL8996266 | 0.86 | FPR2 (0.45) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL1734536 | 0.86 | HDAC1 (0.50) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL9001619 | 0.86 | FPR2 (0.45) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL1734540 | 0.86 | HDAC1 (0.50) | KIF11CA12CA1MMP2MEN1 | |
| SCHEMBL3264266 | 0.84 | CA12 (0.44) | KIF11CA12CA1MMP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118998-A | Preparation method of CETP inhibitor Obicetrapib (AMG-899) | 上海相辉医药科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-1604975-A1 | PROCESSES FOR PRODUCTION OF (R)-3- 4-(TRIFLUOROMETHYL)- PHEN YLAMINO PENTANAMIDE DERIVATIVES | KANEKA CORPORATION (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20040199005-A1 | Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative | KANEKA CORPORATION (JP) | 2004-10-07 | — | — | US | claimed |
| CN-119118998-A | Preparation method of CETP inhibitor Obicetrapib (AMG-899) | 上海相辉医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119118998-A | Preparation method of CETP inhibitor Obicetrapib (AMG-899) | 上海相辉医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-1594843-B1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative | TAKASAGO PERFUMERY CO LTD (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7601842-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-13 | — | — | US | disclosed |
| CN-1972927-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2007-05-30 | — | — | CN | disclosed |
| US-7223859-B2 | Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20040199005-A1 | Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative | KANEKA CORPORATION (JP) | 2004-10-07 | — | — | US | disclosed |
| US-20040199005-A1 | Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative | KANEKA CORPORATION (JP) | 2004-10-07 | — | — | US | disclosed |
| WO-2004083166-A1 | PROCESSES FOR PRODUCTION OF (R)-3-[4-(TRIFLUOROMETHYL)- PHENYLAMINO]PENTANAMIDE DERIVATIVES | KANEKA CORPORATION (JP) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004074255-A2 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-09-02 | — | — | WO | disclosed |
| EP-1425270-A2 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | Pfizer Products Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1383734-A2 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002088069-A9 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PROD INC (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2002088085-A2 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088069-A2 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | AADAT, KMO, ALDH7A1 | KIF11 2810/4885CA12 2615/4885CA1 1662/4885 |
| US-20040199005-A1 | Method for producing (R) -3- [4- (trifluoromethyl) phenylamino] -pentanoic acid amide derivative | CETP, PCTP, MTTP | KIF11 3837/4885CA12 3484/4885CA1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.